Jazz Pharmaceuticals Public
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Jazz Pharmaceuticals Public's revenues will increase 75.7% and EPS will expand 48.4%.
The average estimate for revenue is $190.5 million. On the bottom line, the average EPS estimate is $1.35.
Last quarter, Jazz Pharmaceuticals Public tallied revenue of $181.9 million. GAAP reported sales were much higher than the prior-year quarter's $83.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.53. GAAP EPS of $3.27 for Q4 were 314% higher than the prior-year quarter's $0.79 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 87.2%, 820 basis points worse than the prior-year quarter. Operating margin was 38.0%, much worse than the prior-year quarter. Net margin was 109.2%, much better than the prior-year quarter.
The full year's average estimate for revenue is $825.5 million. The average EPS estimate is $5.82.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 227 members out of 290 rating the stock outperform, and 63 members rating it underperform. Among 73 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 56 give Jazz Pharmaceuticals Public a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $66.91.
- Add Jazz Pharmaceuticals Public to My Watchlist.